Daewoong Pharmaceutical To In-license Almirall's COPD drug Eklira In Korea
This article was originally published in PharmAsia News
Executive Summary
Daewoong signs in-licensing deal just one week before Eklira – a product with a history of clinical setbacks – faces U.S. FDA advisory committee meeting.